Brightsurf Science News & Current Events

June 13, 2015
Patients with primary hand OA should not be prescribed hydroxychloroquine
The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis.

Dose reduction strategy can substantially reduce high cost of TNF inhibitor therapy in RA
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis patients, a good clinical response to maintenance treatment with a tumor necrosis factor inhibitor was maintained even when the dose was reduced by one-third.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.